S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
NASDAQ:SYNH

Syneos Health - SYNH Stock Forecast, Price & News

$34.52
+1.20 (+3.60%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$32.91
$34.54
50-Day Range
$33.32
$40.98
52-Week Range
$22.89
$85.45
Volume
1.00 million shs
Average Volume
1.82 million shs
Market Capitalization
$3.56 billion
P/E Ratio
13.43
Dividend Yield
N/A
Price Target
$54.00

Syneos Health MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
56.4% Upside
$54.00 Price Target
Short Interest
Healthy
6.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
1.09mentions of Syneos Health in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
18.25%
From $2.85 to $3.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

57th out of 1,005 stocks

Commercial Physical Research Industry

5th out of 16 stocks


SYNH stock logo

About Syneos Health (NASDAQ:SYNH) Stock

Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

SYNH Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Should You Exit Your Position in Syneos Health (SYNH)?
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Barclays Keeps Their Sell Rating on Syneos Health (SYNH)
Update: SYNH and RBBN, February 16
See More Headlines
Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

SYNH Company Calendar

Last Earnings
2/16/2023
Today
3/25/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYNH
Employees
29,395
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.00
High Stock Price Forecast
$81.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+56.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$266.50 million
Pretax Margin
5.83%

Debt

Sales & Book Value

Annual Sales
$5.39 billion
Cash Flow
$6.85 per share
Book Value
$33.96 per share

Miscellaneous

Free Float
102,890,000
Market Cap
$3.56 billion
Optionable
Optionable
Beta
1.66

Key Executives

  • Michelle KeefeMichelle Keefe
    Chief Executive Officer & Director
  • Michael BrooksMichael Brooks
    Chief Operating Officer
  • Jason Michael Meggs
    Chief Financial Officer
  • Larry A Pickett
    Chief Information & Digital Officer
  • Baba Shetty
    President-Technology & Data Solutions













SYNH Stock - Frequently Asked Questions

Should I buy or sell Syneos Health stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares.
View SYNH analyst ratings
or view top-rated stocks.

What is Syneos Health's stock price forecast for 2023?

10 brokerages have issued 1 year price targets for Syneos Health's stock. Their SYNH share price forecasts range from $28.00 to $81.00. On average, they anticipate the company's stock price to reach $54.00 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price.
View analysts price targets for SYNH
or view top-rated stocks among Wall Street analysts.

How have SYNH shares performed in 2023?

Syneos Health's stock was trading at $36.68 at the beginning of 2023. Since then, SYNH stock has decreased by 5.9% and is now trading at $34.52.
View the best growth stocks for 2023 here
.

When is Syneos Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our SYNH earnings forecast
.

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) released its quarterly earnings data on Thursday, February, 16th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.08. The business earned $1.36 billion during the quarter, compared to analysts' expectations of $1.29 billion. Syneos Health had a net margin of 4.94% and a trailing twelve-month return on equity of 13.19%.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY 2023 earnings guidance on Monday, February, 20th. The company provided earnings per share (EPS) guidance of $3.26-$3.53 for the period, compared to the consensus estimate of $3.89. The company issued revenue guidance of $4.97 billion-$5.17 billion, compared to the consensus revenue estimate of $5.13 billion.

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Clearbridge Investments LLC (4.03%), Mackenzie Financial Corp (2.25%), JPMorgan Chase & Co. (2.12%), AQR Capital Management LLC (2.10%), Alliancebernstein L.P. (2.05%) and Cooke & Bieler LP (1.83%). Insiders that own company stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends
.

How do I buy shares of Syneos Health?

Shares of SYNH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $34.52.

How much money does Syneos Health make?

Syneos Health (NASDAQ:SYNH) has a market capitalization of $3.56 billion and generates $5.39 billion in revenue each year. The company earns $266.50 million in net income (profit) each year or $2.57 on an earnings per share basis.

How many employees does Syneos Health have?

The company employs 29,395 workers across the globe.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The official website for the company is www.syneoshealth.com. The company can be reached via phone at (919) 876-9300, via email at investor.relations@syneoshealth.com, or via fax at 919-876-9360.

This page (NASDAQ:SYNH) was last updated on 3/26/2023 by MarketBeat.com Staff